Biologics are revolutionizing the treatment of chronic diseases, such as cancer and monogenic disorders, by overcoming the limits of classic therapeutic approaches using small molecules. However, the clinical use of biologics is limited for cardiovascular diseases (CVDs), which are the primary cause of morbidity and mortality worldwide. Here, we review the state-of-the-art use of biologics for cardiac disorders and provide a framework for understanding why they still struggle to enter the field. Some limitations are common and intrinsic to all biological drugs, whereas others depend on the complexity of cardiac disease. In our opinion, delineating these struggles will be valuable in developing and accelerating the approval of a new generation of biologics for CVDs.

Biologics and cardiac disease: challenges and opportunities / G. Ciucci, A. Colliva, R. Vuerich, G. Pompilio, S. Zacchigna. - In: TRENDS IN PHARMACOLOGICAL SCIENCES. - ISSN 0165-6147. - 43:11(2022 Nov), pp. 894-905. [10.1016/j.tips.2022.06.001]

Biologics and cardiac disease: challenges and opportunities

G. Pompilio;
2022

Abstract

Biologics are revolutionizing the treatment of chronic diseases, such as cancer and monogenic disorders, by overcoming the limits of classic therapeutic approaches using small molecules. However, the clinical use of biologics is limited for cardiovascular diseases (CVDs), which are the primary cause of morbidity and mortality worldwide. Here, we review the state-of-the-art use of biologics for cardiac disorders and provide a framework for understanding why they still struggle to enter the field. Some limitations are common and intrinsic to all biological drugs, whereas others depend on the complexity of cardiac disease. In our opinion, delineating these struggles will be valuable in developing and accelerating the approval of a new generation of biologics for CVDs.
biobetters; Biologics; biosimilars; cardiovascular disorders; cell therapy; gene therapy; monoclonal antibodies; recombinant proteins
Settore MED/23 - Chirurgia Cardiaca
nov-2022
29-giu-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0165614722001286-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.94 MB
Formato Adobe PDF
1.94 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/958033
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact